26 studies found for:    Guillain-Barré Syndrome
Show Display Options
Rank Status Study
1 Recruiting International Guillain-Barré Syndrome Outcome Study
Conditions: Guillain-Barré Syndrome;   Miller Fisher Syndrome
Intervention:
2 Unknown  Safety Study of GBS Following Menactra Meningococcal Vaccination
Condition: Guillain-Barre Syndrome
Intervention:
3 Completed Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS)
Condition: Guillain Barre Syndrome
Interventions: Drug: IVIG;   Procedure: Plasma Exchange
4 Suspended Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome
Condition: Guillain-Barre Syndrome
Intervention: Drug: Immune globulin
5 Completed Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-Aminopyridine
Condition: Guillain-Barre Syndrome
Intervention: Drug: 4-aminopyridine (4-AP)
6 Completed Early Mechanical Ventilation for Guillain Barré Syndrome
Conditions: Guillain Barré Syndrome;   Acute Respiratory Failure
Interventions: Procedure: mechanical ventilation;   Procedure: physiotherapy and oxygen if needed
7 Unknown  The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation
Condition: Guillain Barré Syndrome
Intervention:
8 Recruiting Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome
Condition: Guillain-Barré Syndrome
Intervention: Drug: NPB-01
9 Unknown  Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome.
Conditions: Tetraplegia;   Respiratory Failure
Intervention:
10 Not yet recruiting Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study
Condition: Gullian Barre Syndrome
Intervention: Drug: Eculizumab
11 Completed Brain Computer Interface for Communication in ICU: a Feasibility Study
Conditions: Tetraplegia;   Guillain-Barre Syndrome
Intervention:
12 Recruiting Regional Citrate Anticoagulation in Plasma Exchange Treatment
Conditions: Focal Segmental Glomerulosclerosis;   Guillain-Barre Syndrome
Intervention: Procedure: plasma exchange treatment
13 Recruiting Change of Nerve Conduction Properties in IVIg Dependent Neuropathies
Conditions: Guillain-Barre Syndrome;   CIDP;   Multifocal Motor Neuropathy
Intervention:
14 Not yet recruiting Perception and Multisensory Integration in Neurological Patients Using fMRI
Conditions: Acute Inflammatory Demyelinating Polyradiculoneuropathy;   Myasthenia Gravis;   Stroke;   Anosognosia;   Asomatognosia
Intervention: Device: Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla
15 Active, not recruiting Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age
Condition: Observation Safety
Intervention:
16 Active, not recruiting Cervarix Long-term Safety Surveillance
Condition: Infections, Papillomavirus
Interventions: Biological: Cervarix;   Other: Data collection
17 Completed Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801
Condition: Prophylaxis of Ross River Virus Infection
Intervention: Biological: Ross River Virus (RRV) Vaccine
18 Recruiting Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination
Condition: Infections, Meningococcal
Intervention: Biological: Meningococcal conjugate vaccine GSK134612
19 Unknown  Detection of Peripheral Blood Biomarkers in Intermediate Phase Spinal Cord Injury: Correlation With Neurological and Functional Outcomes, and Comparison to Other Central and Peripheral Neurological Conditions.
Condition: Spinal Cord Injury
Intervention:
20 Recruiting Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination
Condition: Infections, Meningococcal
Intervention: Biological: Meningococcal vaccine GSK134612

Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results
Indicates status has not been verified in more than two years